Cargando…
Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862380/ https://www.ncbi.nlm.nih.gov/pubmed/31683667 http://dx.doi.org/10.3390/ijms20215438 |
_version_ | 1783471540557316096 |
---|---|
author | Koltai, Tomas Cardone, Rosa A. Reshkin, Stephan J. |
author_facet | Koltai, Tomas Cardone, Rosa A. Reshkin, Stephan J. |
author_sort | Koltai, Tomas |
collection | PubMed |
description | Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment in very advanced human cancer. However, one of the main limitations of this therapy is its short-term effectiveness: 6 to 12 months, after which resistance develops. pH-centered cancer treatment (pHT) has been proposed as a complementary therapy in cancer, but it has not been adopted or tested as a mainstream protocol, in spite of existing evidence of its advantages and benefits. Many of the factors directly or indirectly involved in MC and anti-angiogenic treatment resistance are appropriately antagonized by pHT. This led to the testing of an association between these two treatments. Preliminary evidence indicates that the association of MC and pHT has the ability to reduce anti-angiogenic treatment limitations and develop synergistic anti-cancer effects. This review will describe each of these treatments and will analyze the fundamentals of their synergy. |
format | Online Article Text |
id | pubmed-6862380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68623802019-12-05 Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer Koltai, Tomas Cardone, Rosa A. Reshkin, Stephan J. Int J Mol Sci Review Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment in very advanced human cancer. However, one of the main limitations of this therapy is its short-term effectiveness: 6 to 12 months, after which resistance develops. pH-centered cancer treatment (pHT) has been proposed as a complementary therapy in cancer, but it has not been adopted or tested as a mainstream protocol, in spite of existing evidence of its advantages and benefits. Many of the factors directly or indirectly involved in MC and anti-angiogenic treatment resistance are appropriately antagonized by pHT. This led to the testing of an association between these two treatments. Preliminary evidence indicates that the association of MC and pHT has the ability to reduce anti-angiogenic treatment limitations and develop synergistic anti-cancer effects. This review will describe each of these treatments and will analyze the fundamentals of their synergy. MDPI 2019-10-31 /pmc/articles/PMC6862380/ /pubmed/31683667 http://dx.doi.org/10.3390/ijms20215438 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Koltai, Tomas Cardone, Rosa A. Reshkin, Stephan J. Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer |
title | Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer |
title_full | Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer |
title_fullStr | Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer |
title_full_unstemmed | Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer |
title_short | Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer |
title_sort | synergy between low dose metronomic chemotherapy and the ph-centered approach against cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862380/ https://www.ncbi.nlm.nih.gov/pubmed/31683667 http://dx.doi.org/10.3390/ijms20215438 |
work_keys_str_mv | AT koltaitomas synergybetweenlowdosemetronomicchemotherapyandthephcenteredapproachagainstcancer AT cardonerosaa synergybetweenlowdosemetronomicchemotherapyandthephcenteredapproachagainstcancer AT reshkinstephanj synergybetweenlowdosemetronomicchemotherapyandthephcenteredapproachagainstcancer |